Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3515-3521

  Markovic, O ^a   Marisavljevic, D ^a,c   Cemerikic Martinovic, V ^b   Martinovic, T ^c   Filipovic, B ^a   Stanisavljevic, D ^d   Zivkovic R ^a   Hajder, J ^a   Stanisavljevic, N ^a   Mihaljevic, B ^c,d  

^a KBC Bežanijska Kosa ^*  (Serbia)

^b Beo Lab   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Apoptosis; Diffuse large B cell lymphoma; Immunohistochemistry; Prognosis; Survivin

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; KI 67 ANTIGEN; PREDNISONE; RITUXIMAB; SURVIVIN; VINCRISTINE; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; R CHOP PROTOCOL; R-CHOP PROTOCOL; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTINUOUS INFUSION; CYTOPLASM; DRUG MEGADOSE; EXTRANODAL LOCALIZATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; AGED; AREA UNDER THE CURVE; BIOSYNTHESIS; CANCER STAGING; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 84880280960     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0232-x     Document Type: Article

References (31)

1. Paepe PD, Wolf-Peeters CD. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia. 2007;21:37-43.
2. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005;23(26):6387-93.
3. Cory and Adams. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647-56.
4. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3(6):401-10.
5. Altieri D. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46-54.
6. Jacquemin G, Granci V, Gallouet SA, et al. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica. 2012;97(1):38-46.
7. Sung JY, Sung JL, Kim YW, Lee J. Prognostic significance of pSTAT3 and Survivin expression in diffuse large B-cell lymphoma. BAAP. 2010;3(1):7-13.
8. Muris JJ, Cillessen SA, Vos W, Van Houdt IS, et al. Immunohistochemical profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005;105:2916-22.
9. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921-5.
10. Muris JJ, Meijer CJ, Ossenkoppele GJ, Vos W, Oudejans JJ. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. Hematol Oncol. 2006;24(3):97-104.
11. Mainou-Fowler T, Overman LM, Dignum H, et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol. 2008;32(1):59-68.
12. Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U. Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leuk Res. 2008;32(2):243-50.
13. Mitrović Z, Ilić I, Aurer I, et al. Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathol Oncol Res. 2011;17(2):243-7.
14. Jaffe ES, Harris NL, Stein H, editors. World Health Organization classification of tumours pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
15. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Costwolds meeting. J Clin Oncol. 1989;7(11):1630-6.
16. The international Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-94.
17. Hans CP, Weisenburger D, Greiner CG, Gascoyne RD, Delabie J, Ott G. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82.
18. Cheson BD, Homing SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-9.
19. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;8:917-21.
20. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24:1994-2007.
21. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, Caspases and Anticancer Drugs. Cancer Res. 1998;58:5315-20.
22. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-9.
23. Li F. Role of surviving and its splice variants in tumorigenesis. Br J Cancer. 2005;92:212-6.
24. Deveraux QL, Reed J. IAP family proteins-suppressors of apoptosis. Genes and Development, Cold Spring Harbor. 1999;13:239-52.
25. Small S, Keerthivasan G, Huang Z, Gurbuxani S. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010;24(11):120-6.
26. Song KY, Jung CK, Park WS, Park CH. Expression of the Antiapoptosis Gene Survivin Predicts Poor Prognosis of Stage III Gastric Adenocarcinoma. Jpn J Clin Oncol. 2009;39(5):290-6.
27. Ikeguchi M, Ueda U, et al. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol. 2002;11(1):33-4.
28. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia Hematologica. 2007;92(8):1043-50.
29. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111:196-203.
30. Ansell SM, Arendt BK, Grote DM, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkins lymphoma. Leukemia. 2004;18(3):616-623.
31. Watanuki-Miyauchi R, Kojima Y, Tsurumi H, et al. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Intern. 2005;55:324-30.